Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry

Haematologica. 2024 Aug 1;109(8):2682-2687. doi: 10.3324/haematol.2023.284601.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • CCAAT-Enhancer-Binding Proteins* / genetics
  • Female
  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / genetics
  • Male
  • Middle Aged
  • Mutation*
  • Prognosis
  • Registries
  • Spain / epidemiology

Substances

  • CCAAT-Enhancer-Binding Proteins
  • CEBPA protein, human

Grants and funding

Funding: This investigation was partially supported by Instituto de Salud Carlos III, Spain, grant PMP22/00069 and PI19/00730.